Sessions

MARKET ACCESS & REIMBURSEMENT: REAL WORLD EVIDENCE & VALUE DEFINITION
THE ROLE OF NEW & ENABLING TECHNOLOGIES TO DRIVE EUROPEAN CGT COMMERCIALISATION SUCCESS
STRUCTURING YOUR LOCATION & FACILITY DESIGN TO ENSURE COMMERCIAL SUCCESS
INVESTING IN INVESTMENT: THE LONG TERM STRATEGY FOR CGT GROWTH IN EUROPE

MARKET ACCESS & REIMBURSEMENT: REAL WORLD EVIDENCE & VALUE DEFINITION

01 Sep 2022
11:00

11:00 – CHAIR INTRODUCTION

Chair: Alexander Natz , Secretary-General, EUCOPE

 

11:05 – FIRESIDE CHAT

Speakers:

Nicola Redfern, Former Vice President Northern Europe, Blue Bird Bio

Lisa Deschamps, CEO, AviadoBio

Mark Trusheim, Strategic Director, NEWDIGS and Visiting Scientist, Massachusetts Institute of Technology (MIT)

 

11:30 – CASE STUDY: MITIGATING HEMOPHILIA & SICKLE CELL DISEASE DURABLE THERAPY UNCERTAINTIES WITH RWE DRIVEN PAYMENT INNOVATION 

Speaker: Mark Trusheim, Strategic Director, NEWDIGS and Visiting Scientist, Massachusetts Institute of Technology (MIT) 

 

11:45 – FIRESIDE CHAT

Speakers:

Francesca Pasinelli, Direttore Generale, Fondazione Telethon

 

12:00 – CASE STUDY: AN INTRODUCTION: THE INNOVATION MEDICINES FUND

Speaker: Nina Pinwell, Head of Commercial Operations, NHS England

 

12:15 – Q&A SESSION WITH DEEP DIVE SPEAKERS

Speakers:

Mark Trusheim, Strategic Director, NEWDIGS and Visiting Scientist, Massachusetts Institute of Technology (MIT) 

Francesca Pasinelli, Direttore Generale, Fondazione Telethon

Nina Pinwell, Head of Commercial Operations, NHS England

Speakers

Alexander Natz
Secretary General
EUCOPE
Nicola Redfern
Former Vice President Northern Europe
Bluebird Bio
Lisa Deschamps
Chief Executive Officer
AviadoBio
Mark Trusheim
Strategic Director, NEWDIGS and Visiting Scientist,
Massachusetts Institute of Technology (MIT)
Francesca Pasinelli
Director General
Fondazione Telethon
Nina Pinwell
Head of Commercial Operations
NHS England